



CDs as solubilizers: Effects of excipients and competing drugs

Phatsawee Jansook, Thorsteinn Loftsson*

Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, IS-107 Reykjavik, Iceland

ARTICLE INFO

Article history:

Received 24 February 2009

Received in revised form 2 June 2009

Accepted 3 June 2009

Available online 12 June 2009

Keywords:

Cyclodextrins

Formulation

Solubility

Aggregates

Permeation

Availability

ABSTRACT

In recent years cyclodextrins (CDs) have been acknowledged by the pharmaceutical industry as very useful enabling excipients for solubilization and stabilization of drugs in aqueous formulations. Their effect is however strongly influenced by other commonly used excipients. The purpose of this investigation was to examine the effects of excipients and drug combinations on the effects of CD solubilization of drugs and drug availability. The model drug was dexamethasone, the competing drugs tested were hydrocortisone, indomethacin and amphotericin B, and the sample CDs were γ -cyclodextrin (γ CD) and 2-hydroxypropyl- γ -cyclodextrin (HP γ CD). Benzalkonium chloride and hydroxypropyl methylcellulose enhance the solubilizing effect of the CDs whereas in general EDTA decreased the effect. The effect of second drug present in the aqueous formulation did depend on the affinity of that drug for the CD. Drugs which readily formed complexes with the CDs (e.g. hydrocortisone) decreased their ability to solubilize dexamethasone. Drugs that have little affinity for CDs (e.g. amphotericin B) did in some cases improve the CD solubilization of dexamethasone. Flux diagrams obtained through semi-permeable cellophane membrane indicated that drug/CD complexes self-assemble to form aggregates, especially at CD concentrations above 5% (w/v). This aggregate formation was affected by the excipients and did influence drug availability from the formulations.

© 2009 Elsevier B.V. All rights reserved.

1. Introduction

Cyclodextrins (CDs) are cyclic torus-shaped molecules, consisting of 6–8 D-(+)-glucopyranose units with hydrophilic outer surface and lipophilic central cavity. During the past two decades CDs have received growing attention, mainly due to their ability to increase aqueous solubility and stability of poorly water-soluble drugs through formation of inclusion complexes (Brewster and Loftsson, 2007; Loftsson and Duchêne, 2007). Furthermore CDs can act as permeation enhancers by keeping hydrophobic drug molecules in solution and deliver them to the surface of a biological membrane, thus leading to improve transepithelial permeation and bioavailability of drug (Loftsson et al., 2007). Pharmaceutical excipients that are present in a given drug formulation can enhance or decrease the solubilizing effect of CDs (Loftsson and Brewster, 1996; Loftsson et al., 1999). Polymers can enhance the CD complexation of drugs and they can enhance the drug permeation through biological membranes, possibly through formation of ternary complexes or co-complexes (Jarho et al., 1998; Kristinsson et al., 1996; Loftsson, 1998; Mura et al., 2001; Chowdary and Srinivas, 2006). Frequently dosage forms contain more than one active ingredient. Dexamethasone can, for example, be found in various combination eye drops such as eye drops containing dexamethasone, neomycin

and polymyxin B, and eye drops containing dexamethasone and tobramycin. However, combination products containing CD have not been marketed.

The purpose of the present investigation is to study the influence of common pharmaceutical excipients, as well as that of competing drugs, on the CD solubilization of drugs that possess poor solubility in water and their availability. Aqueous eye drop solution was used as a sample formulation with dexamethasone as a model drug. The tested competing drugs were hydrocortisone, which has similar steroidal structure as dexamethasone, indomethacin, which is a carboxylic acid fully ionized at physiologic pH, and amphotericin B, which is a water-insoluble polyene antibiotic that has low affinity for the CD central cavity. The sample CDs were γ -cyclodextrin (γ CD), which has limited solubility in water, and its water-soluble derivative 2-hydroxypropyl- γ -cyclodextrin (HP γ CD). Previous studies have shown that mixtures of γ CD and HP γ CD can be more potent solubilizers than the individual CDs (Jansook and Loftsson, 2008). Thus, mixtures of γ CD and HP γ CD were also included in this study. The physicochemical properties of the excipients and sample compounds are shown in Table 1.

2. Materials and methods










2.1. Materials

Dexamethasone (Dx) was purchased from Fagron group (Amsterdam, Netherlands), hydrocortisone (HC) from ICN Biomedicals

* Corresponding author. Tel.: +354 525 4464; fax: +354 525 4071.
E-mail address: thorstlo@hi.is (T. Loftsson).

Table 1

Physicochemical properties of the excipients and sample compounds (Lavasanifar et al., 2002; Moffat et al., 2004; Nokhodchi et al., 2005; Brewster and Loftsson, 2007).

Physicochemical properties	(A)					
	Dexamethasone	Hydrocortisone	Indomethacin	Amphotericin B	γ CD	HP γ CD ^a
Chemical structure						
Molecular weight	392.5	362.5	357.8	924.1	1297.1	1576
Melting point (°C) ^b	270 (dec.)	214 (dec.)	158	>170 (dec.)	≥200 (dec.)	≥200 (dec.)
ζ_a	-	-	4.5	5.5; 10	-	-
Octanol/water partition coefficient (mg/ml) in water (at RT)	1.8	1.6	-1.0 (at pH 7.4)	0.8	-12	<-10
Physicochemical properties	(B)					
	Edetate disodium		Benzalkonium chloride		Hydroxypropylmethylcellulose	
Chemical structure						
Molecular weight	336.2		360 (average)		10,000–1,500,000 (approximately)	
Melting point (°C) ^b	252 (dec.)		≈40		190–200 (browns)	
ζ_a	2.0; 2.7; 6.2; 10.3		-		-	
Octanol/water partition coefficient (mg/ml) in water (at RT)	96		9.98 for C ₁₂ ; 32.9 for C ₁₄ ; 82.5 for C ₁₆ ^c		Varies with the viscosity	
			Very soluble			

^a Representative structure.

^b Dec.: decomposition upon heating.

^c Varies with the alkyl chain length of the homolo.




Fig. 1. The effect of additives in aqueous CD solution on the solubility and the flux of dexamethasone through semi-permeable cellophane membrane MWCO 3500; (A) γ CD; (B) γ CD/HP γ CD (ratio 80:20); (C) γ CD/HP γ CD (ratio 20:80); (D) HP γ CD; (◆) EDTA (0.1%, w/v); (◇) BAC (0.02%, w/v); (■) HPMC (0.1%, w/v); (□) all excipients (i.e. in the aqueous eye drop formulation).

Table 2
HPLC conditions.

Drugs	Mobile phase ^a	Flow rate (ml/min)	Wavelength (nm)	Retention time (min)
Dexamethasone	ACN:THF:water (33:1:66)	1.5	241	5.1
Dexamethasone Hydrocortisone	ACN:THF:water (33:1:66)	1.4	241 and 254	5.1 and 3.0
Dexamethasone Indomethacin	ACN:0.5% acetic acid (50:50)	1.5	240 and 240	7.2 and 1.9
Dexamethasone amphotericin B	ACN:0.25 mM EDTA (37:63)	1.0	241 and 403	4.4 and 3.1

^a Volume ratios. ACN: acetonitrile; THF: tetrahydrofuran; acetic acid: aqueous acetic acid solution; EDTA: aqueous disodium edetate dehydrate solution.

(Aurora, OH), amphotericin B (AmB) and indomethacin (IDM) from Sigma (St. Louis, MO), γ -cyclodextrin (γ CD) and 2-hydroxypropyl- γ -cyclodextrin (HP γ CD) MS 0.6 (MW 1576 Da) from Wacker Chemie (Munich, Germany), disodium edetate dehydrate (EDTA) and sodium chloride (NaCl) from Merck (Darmstadt, Germany), benzalkonium chloride (BAC) and hydroxypropyl methylcellulose 4000 (HPMC) from Sigma (St. Louis, MO), semi-permeable cellophane membranes (SpectaPor[®], molecular weight cut-off (MWCO) 3500) from Spectrum Europe (Breda, Netherlands). All other chemicals used were of analytical reagent grade purity. Milli-Q (Millipore, Bedford, MA) water was used for the preparation of all solutions.

2.2. Solubility determinations

Solubility of dexamethasone and in water or aqueous CD solutions was determined by heating in autoclave (121 °C for 20 min) (Loftsson and Hreinsdóttir, 2006). Excess amount of dexamethasone was added to an aqueous solution containing 0–20% (w/v) CD (pure γ CD, pure HP γ CD, or a mixture of γ CD and HP γ CD), benzalkonium chloride (0.02%, w/v), EDTA (0.1%, w/v) and/or hydroxypropyl methylcellulose (HPMC) (0.1% w/v), individual compounds or mixtures thereof. The effect of HPMC on the solubility of dexamethasone was determined in 0.10–0.75% (w/v) HPMC solutions in pure water. The suspensions formed were heated in autoclave at 121 °C for 20 min in sealed glass vials and then allowed to cool to room temperature. Then small amount of solid drug was added to the suspensions, pH adjusted to 7.4 with concentrated aqueous hydroxide solution, and the suspension allowed to equilibrate in the resealed vials at room temperature (22–23 °C) for 7 days under constant agitation. Many drugs such as indomethacin are known to exist in more than one polymorphic form and thus it is essential to add small amount of the solid drug to the test media after heating. After equilibrium was attained, the suspensions were filter through 0.45 μ m membrane filters, the filtrates diluted with mobile phase and analyzed by HPLC. The phase-solubility profiles were determined according to Higuchi and Connors (1965).

Co-complexation of two different drugs was also investigated. In that case excess of both dexamethasone and a second drug (hydrocortisone, indomethacin or amphotericin B) were simultaneously added to the aqueous complexation media and the solubility of both drugs determined as previously described, except when the chemically instable amphotericin B was present then heating in an autoclave was replaced by heating in an ultrasonic bath at 60 °C for




Fig. 2. The phase solubility diagrams of dexamethasone and the determined γ CD content in aqueous γ CD solution containing no additives and with additives; (●) no additive; (◆) EDTA (0.1% w/v); (◇) BAC (0.02%, w/v); (■) HPMC (0.1%, w/v); (□) all excipients (i.e. in the aqueous eye drop formulation). The aqueous cyclodextrin solutions were in all cases saturated with dexamethasone.

Table 3
Effect of additives on dexamethasone CE using the CE obtained in aqueous complexation medium without additives as a reference.

The additives ^a	γ CD ^b		HP γ CD		γ CD/HP γ CD			
	CE	Ratio	CE	Ratio	(80/20) ^b		(20/80)	
					CE	Ratio	CE	Ratio
No additive	0.14 ± 0.01	1.00	1.11 ± 0.05	1.00	0.62 ± 0.03	1.00	1.44 ± 0.02	1.00
EDTA	0.12 ± 0.01	0.88	1.28 ± 0.02	1.15	0.52 ± 0.03	0.85	1.16 ± 0.03	0.81
BAC	0.21 ± 0.02	1.57	1.26 ± 0.01	1.14	0.71 ± 0.04	1.16	1.23 ± 0.03	0.85
HPMC	0.17 ± 0.02	1.25	1.24 ± 0.03	1.11	0.69 ± 0.01	1.13	1.02 ± 0.01	0.71
EDTA + BAC + HPMC	0.27 ± 0.02	1.95	1.31 ± 0.02	1.18	0.87 ± 0.02	1.42	1.41 ± 0.01	0.98

^a Concentration of additives: EDTA 0.1% (w/v); BAC 0.02% (w/v); HPMC 0.1% (w/v).




Fig. 3. The effect of a second drug in aqueous CD solution on phase solubility profiles of dexamethasone and its second drug in pure and different ratios of γ CD/HP γ CD mixtures in the aqueous eye drop formulation: (A) dexamethasone (DX); (B) hydrocortisone (HC); (C) indomethacin (IDM); (D) amphotericin B (AmB). γ CD (\blacklozenge); γ CD/HP γ CD ratio (80/20) (\diamond); (\square) γ CD/HP γ CD ratio (20/80); (\blacksquare) HP γ CD.

30 min. The complexation efficiency (CE) was determined from the linear phase-solubility diagrams (plots of the total drug solubility ($[drug]_t$) versus total CD concentration ($[CD]_t$) in moles per liter) (Loftsson et al., 2005):

$$CE = \frac{\text{Slope}}{1 - \text{Slope}} = \frac{[drug/CD \text{ complex}]}{[CD]} = K_{1:1} \cdot S_0 \quad (1)$$

where $K_{1:1}$ is the stability constant of the drug/CD 1:1 complex and S_0 is the intrinsic solubility of the drug.

2.3. Quantitative determinations

Quantitative determinations of the individual drugs were performed on a reversed-phase high performance liquid chromatographic (HPLC) component system consisting of Hewlett Packard Series 1100, consisting of a G132A binary pump with a G1379A sol-

auto sampler, and Phenomenex Luna 5 μ C18 reverse-phase column (150 mm \times 4.6 mm). The HPLC chromatographic conditions are shown in Table 2. Quantitative analysis of γ CD content was determined by HPLC (Dionex UltiMate 3000, USA). The liquid chromatograph comprised of an UltiMate 3000 and a differential refractive index detector (Shodex RI-101, Japan) with a sensitivity of 600 μ RIU. Data integration was done using CHROMELEON[®] software version 6.80 for LC integration. The column used was Luna NH₂ 100A (10 μ m, 250 mm \times 4.6 mm) (Phenomenex, USA). The HPLC conditions were as follows. Mobile phase: 67% (v/v) acetonitrile in pure water; flow rate: 1 ml/min; injection volume: 20 μ l; and column oven temperature: 25 $^\circ$ C.

2.4. Permeation studies

The permeability studies of dexamethasone, hydrocortisone,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.